(ABBV) AbbVie - Ratings and Ratios
Biologics, Immunology, Oncology, Neuroscience, Eye Care
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.30% |
| Yield on Cost 5y | 7.29% |
| Yield CAGR 5y | 5.98% |
| Payout Consistency | 100.0% |
| Payout Ratio | 70.4% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 24.2% |
| Value at Risk 5%th | 33.8% |
| Relative Tail Risk | -15.05% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.05 |
| Alpha | 25.49 |
| CAGR/Max DD | 0.91 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.332 |
| Beta | 0.399 |
| Beta Downside | 0.599 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.74% |
| Mean DD | 7.13% |
| Median DD | 6.67% |
Description: ABBV AbbVie December 02, 2025
AbbVie Inc. (NYSE: ABBV) is a research-driven biopharmaceutical firm headquartered in North Chicago, Illinois, that develops, manufactures, and markets a broad portfolio of prescription medicines across immunology, oncology, neuroscience, eye care, virology, and specialty therapeutics.
The company’s flagship products include Humira (autoimmune diseases), Skyrizi (psoriasis and ulcerative colitis), Rinvoq (inflammatory disorders), Imbruvica and Venclexta (hematologic cancers), and a suite of neuroscience and eye-care drugs such as Vraylar, Duopa, Ozurdex, and Restasis. Recent pipeline additions feature Elahere for solid tumors and Epkinly for lymphoma, expanding AbbVie’s oncology footprint.
Key recent metrics (FY 2023) show revenue of roughly $58 billion, with Humira still contributing about $2.5 billion in Q1 2024 despite biosimilar competition-a sign of pricing resilience. R&D spending remained high at ~ $6.5 billion, reflecting a commitment to pipeline growth, while the dividend yield hovered near 4.8 %, making the stock attractive to income-focused investors. Primary sector drivers include an aging global population that fuels demand for chronic-disease therapies and a competitive landscape where patent expirations and biosimilar entry pressure pricing dynamics.
For a deeper quantitative breakdown of AbbVie’s valuation metrics, you might explore the analyst tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 2.39b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 4.47 > 1.0 |
| NWC/Revenue: -18.19% < 20% (prev -27.51%; Δ 9.32% < -1%) |
| CFO/TA 0.16 > 3% & CFO 20.86b > Net Income 2.39b |
| Net Debt (63.11b) to EBITDA (12.79b): 4.93 < 3 |
| Current Ratio: 0.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.77b) vs 12m ago 0.0% < -2% |
| Gross Margin: 69.74% > 18% (prev 0.67%; Δ 6907 % > 0.5%) |
| Asset Turnover: 43.01% > 50% (prev 38.72%; Δ 4.29% > 0%) |
| Interest Coverage Ratio: 1.55 > 6 (EBITDA TTM 12.79b / Interest Expense TTM 2.92b) |
Altman Z'' -0.78
| A: -0.08 (Total Current Assets 28.54b - Total Current Liabilities 39.39b) / Total Assets 133.90b |
| B: -0.11 (Retained Earnings -14.23b / Total Assets 133.90b) |
| C: 0.03 (EBIT TTM 4.54b / Avg Total Assets 138.66b) |
| D: -0.12 (Book Value of Equity -15.79b / Total Liabilities 136.50b) |
| Altman-Z'' Score: -0.78 = CCC |
Beneish M -3.14
| DSRI: 1.04 (Receivables 12.77b/11.47b, Revenue 59.64b/55.53b) |
| GMI: 0.96 (GM 69.74% / 67.21%) |
| AQI: 0.97 (AQ_t 0.75 / AQ_t-1 0.77) |
| SGI: 1.07 (Revenue 59.64b / 55.53b) |
| TATA: -0.14 (NI 2.39b - CFO 20.86b) / TA 133.90b) |
| Beneish M-Score: -3.14 = AA |
ValueRay F-Score (Strict, 0-100) 52.59
| 1. Piotroski: 4.0pt |
| 2. FCF Yield: 4.61% |
| 3. FCF Margin: 34.49% |
| 4. Debt/Equity: -26.02 |
| 5. Debt/Ebitda: 4.93 |
| 6. ROIC - WACC: -1.24% |
| 7. RoE: 498.8% |
| 8. Revenue Trend: 18.54% |
| 9. EPS Trend: -71.13% |
What is the price of ABBV shares?
Over the past week, the price has changed by +2.29%, over one month by -3.39%, over three months by -3.17% and over the past year by +32.78%.
Is ABBV a buy, sell or hold?
- Strong Buy: 12
- Buy: 4
- Hold: 12
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ABBV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 244.6 | 11.6% |
| Analysts Target Price | 244.6 | 11.6% |
| ValueRay Target Price | 268.3 | 22.4% |
ABBV Fundamental Data Overview January 24, 2026
P/E Forward = 15.4321
P/S = 6.4228
P/B = 50.4573
P/EG = 0.3879
Revenue TTM = 59.64b USD
EBIT TTM = 4.54b USD
EBITDA TTM = 12.79b USD
Long Term Debt = 62.97b USD (from longTermDebt, last quarter)
Short Term Debt = 5.77b USD (from shortTermDebt, last quarter)
Debt = 68.74b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 63.11b USD (from netDebt column, last quarter)
Enterprise Value = 446.15b USD (383.08b + Debt 68.74b - CCE 5.67b)
Interest Coverage Ratio = 1.55 (Ebit TTM 4.54b / Interest Expense TTM 2.92b)
EV/FCF = 21.69x (Enterprise Value 446.15b / FCF TTM 20.57b)
FCF Yield = 4.61% (FCF TTM 20.57b / Enterprise Value 446.15b)
FCF Margin = 34.49% (FCF TTM 20.57b / Revenue TTM 59.64b)
Net Margin = 4.01% (Net Income TTM 2.39b / Revenue TTM 59.64b)
Gross Margin = 69.74% ((Revenue TTM 59.64b - Cost of Revenue TTM 18.05b) / Revenue TTM)
Gross Margin QoQ = 66.38% (prev 71.82%)
Tobins Q-Ratio = 3.33 (Enterprise Value 446.15b / Total Assets 133.90b)
Interest Expense / Debt = 1.14% (Interest Expense 781.0m / Debt 68.74b)
Taxrate = 21.0% (US default 21%)
NOPAT = 3.59b (EBIT 4.54b * (1 - 21.00%))
Current Ratio = 0.72 (Total Current Assets 28.54b / Total Current Liabilities 39.39b)
Debt / Equity = -26.02 (negative equity) (Debt 68.74b / totalStockholderEquity, last quarter -2.64b)
Debt / EBITDA = 4.93 (Net Debt 63.11b / EBITDA 12.79b)
Debt / FCF = 3.07 (Net Debt 63.11b / FCF TTM 20.57b)
Total Stockholder Equity = 480.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.73% (Net Income 2.39b / Total Assets 133.90b)
RoE = 498.8% (Net Income TTM 2.39b / Total Stockholder Equity 480.0m)
RoCE = 7.16% (EBIT 4.54b / Capital Employed (Equity 480.0m + L.T.Debt 62.97b))
RoIC = 5.16% (NOPAT 3.59b / Invested Capital 69.54b)
WACC = 6.39% (E(383.08b)/V(451.82b) * Re(7.38%) + D(68.74b)/V(451.82b) * Rd(1.14%) * (1-Tc(0.21)))
Discount Rate = 7.38% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 84.16% ; FCFF base≈18.59b ; Y1≈18.34b ; Y5≈18.90b
Fair Price DCF = 238.8 (EV 485.23b - Net Debt 63.11b = Equity 422.12b / Shares 1.77b; r=6.39% [WACC]; 5y FCF grow -2.17% → 2.90% )
EPS Correlation: -71.13 | EPS CAGR: -14.25% | SUE: -4.0 | # QB: 0
Revenue Correlation: 18.54 | Revenue CAGR: 1.56% | SUE: 0.41 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.10 | Chg30d=-0.009 | Revisions Net=+2 | Analysts=13
EPS next Year (2026-12-31): EPS=14.24 | Chg30d=-0.020 | Revisions Net=+0 | Growth EPS=+36.6% | Growth Revenue=+9.5%
Additional Sources for ABBV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle